# A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

> **NCT03787758** · PHASE1 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** SAGE-718

## Key facts

- **NCT ID:** NCT03787758
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2019-10-07
- **Final completion:** 2019-10-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03787758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03787758, "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03787758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*